ArticleRadiation research2011
Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.
Article in Radiation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 78 citations in OpenAlex.
- Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123.American journal of clinical oncology · 2018Trial
- Trial
- C. Norman Coleman's Legacy in Radiation Research and Global Health: A Cancer Research and Care Perspective.Disaster medicine and public health preparedness · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- Development of animal models with chronic kidney disease-mineral and bone disorder based on clinical characteristics and pathogenesis.Frontiers in endocrinology · 2025Review
- Noninvasive Quantification of Radiation-Induced Lung Injury Using a Targeted Molecular Imaging Probe.International journal of radiation oncology, biology, physics · 2024Article
- Delayed renal injury in survivors of hematologic acute radiation syndrome.International journal of radiation biology · 2023Article
- The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.International journal of radiation biology · 2023Review
- IPW-5371 mitigates the delayed effects of acute radiation exposure in WAG/RijCmcr rats when started 15 days after PBI with bone marrow sparing.International journal of radiation biology · 2023Article
- Inter-agency perspective: Translating advances in biomarker discovery and medical countermeasures development between terrestrial and space radiation environments.Life sciences in space research · 2022Article
- Vascular regression in the kidney: changes in 3D vessel structure with time post-irradiation.Biomedical optics express · 2022Article
- Pharmacologic ACE-Inhibition Mitigates Radiation-Induced Pneumonitis by Suppressing ACE-Expressing Lung Myeloid Cells.International journal of radiation oncology, biology, physics · 2022Article
- Scientific research and product development in the United States to address injuries from a radiation public health emergency.Journal of radiation research · 2021Article
- Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.Frontiers in pharmacology · 2021Review
- Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.Frontiers in pharmacology · 2021Article
- Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities.Frontiers in pharmacology · 2021Article
- Targets for protection and mitigation of radiation injury.Cellular and molecular life sciences : CMLS · 2020Review
- Wound Trauma Exacerbates Acute, but not Delayed, Effects of Radiation in Rats: Mitigation by Lisinopril.International journal of molecular sciences · 2020Article
- Losartan Treatment Could Improve the Outcome of TBI Mice.Frontiers in neurology · 2020Article
- Effects of Diet on Late Radiation Injuries in Rats.Health physics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
It is known that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can be used to mitigate radiation-induced renal injury. However, for a variety of reasons, these previous results are not directly applicable to the development of agents for the mitigation of injuries caused by terrorism-related radiation exposure. As part of an effort to develop an animal model that would fit the requirements of the U.S. Food and Drug Administration (FDA) "Animal Efficacy Rule", we designed new studies which used an FDA-approved ACEI (captopril) or an FDA-approved ARB (losartan, Cozaar®) started 10 days after a single total-body irradiation (TBI) at drug doses that are equivalent (on a g/m(2)/day basis) to the doses prescribed to humans. Captopril and losartan were equally effective as mitigators, with DMFs of 1.23 and 1.21, respectively, for delaying renal failure. These studies show that radiation nephropathy in a realistic rodent model can be mitigated with relevant doses of FDA-approved agents. This lays the necessary groundwork for pivotal rodent studies under the FDA Animal Efficacy Rule and provides an outline of how the FDA-required large-animal studies could be designed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.